Quality of advanced ovarian cancer surgery: A French assessment of ESGO quality indicators.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
02 2021
Historique:
received: 14 05 2020
revised: 28 07 2020
accepted: 05 08 2020
pubmed: 31 8 2020
medline: 23 4 2021
entrez: 1 9 2020
Statut: ppublish

Résumé

In 2016, the European Society of Gynecology Oncology (ESGO) published indicators defining the quality of surgical management of advanced ovarian cancer. The objective of the study was to assess the quality of ovarian cancer patient management in regional centers authorized for gynecological cancer, based on the ESGO list of quality indicators. A multicenter retrospective observational cohort study was conducted from January 1 to June 30, 2016. The following quality indicators 1 "rate of complete surgical resection", 4 "center participating in clinical trials in gynecologic oncology", 5 "treatment planned and reviewed at a multidisciplinary team meeting", 6 "required preoperative workup", 8 "minimum required elements in operative reports" and 9 "minimum required elements in pathology reports" were selected. 91 patients were evaluated in 16 centers. The required preoperative workup was incomplete in 25% of cases. Treatment was not planned at a multidisciplinary team meeting for 24%. An evaluation score of peritoneal involvement was included in 40% of the operative reports and the quality of surgical resection was reported in 72%. Primary surgery was most often performed in a peripheral hospital (48%), interval surgery in a private center (37%), and closure surgery in a regional cancer center (43%). No institution respected the six quality indicators evaluated. One regional cancer center respected five items and two private centers did not respect any. Whilst the ESGO quality indicators provide objective, validated and evaluable support which centers can use to improve quality of care, we observed heterogeneous practices amongst the centers evaluated.

Identifiants

pubmed: 32863097
pii: S0748-7983(20)30695-8
doi: 10.1016/j.ejso.2020.08.003
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

360-366

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Marie-Mélanie Gac (MM)

Department of Surgical Oncology, Institut Cancérologie de L'Ouest, Nantes, Saint Herblain, France.

Cécile Loaec (C)

Department of Surgical Oncology, Institut Cancérologie de L'Ouest, Nantes, Saint Herblain, France. Electronic address: cecile.loaec@ico.unicancer.fr.

Johanna Silve (J)

Onco Pays de La Loire, Plateau des écoles, 50 Route de Saint-Sébastien, 44093, Nantes, France.

Edouard Vaucel (E)

Department of Obstetrics and Gynecology, CHU de Nantes, France.

Paule Augereau (P)

Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Angers, France.

Romuald Wernert (R)

Department of Surgical Oncology, Institut de Cancérologie de L'Ouest, Angers, France.

Charlotte Bourgin (C)

Department of Surgical Oncology, Institut Cancérologie de L'Ouest, Nantes, Saint Herblain, France.

Xavier Aireau (X)

Department of Obstetrics and Gynecology, Centre Hospitalier de Cholet, France.

Alain Lortholary (A)

Confluent Private Hospital, Institut de Cancérologie Catherine de Sienne, Nantes, France.

Philippe Descamps (P)

Department of Obstetrics and Gynecology, CHU Angers, France.

Frank Priou (F)

CHD Vendee-Hopital Les Oudairies, La Roche Sur Yon, France.

Pascaline Deblaye (P)

CHD Vendee-Hopital Les Oudairies, La Roche Sur Yon, France.

Hugues Bourgeois (H)

Department of Medical Oncology, Clinique Victor Hugo, Le Mans, France.

Valérie Delecroix (V)

Clinique Mutualiste de L'Estuaire, Saint-Nazaire, France.

Fabienne Empereur (F)

Onco Pays de La Loire, Plateau des écoles, 50 Route de Saint-Sébastien, 44093, Nantes, France.

Loïc Campion (L)

Biometrics, Institut de Cancérologie de L'Ouest, Centre René Gauducheau, Saint-Herblain, France; CRCINA, University of Nantes, INSERM UMR1232, CNRS-ERL6001, Nantes, France.

Jean-Marc Classe (JM)

Department of Surgical Oncology, Institut Cancérologie de L'Ouest, Nantes, Saint Herblain, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH